CRC_ACE CL 006

ACE CL 006 A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

This study is designed to evaluate PFS endpoint for ACE-196 vs ibrutinib in previously treated chronic lymphocytic leukemia.

Key Inclusion Criteria:

•ECOG 0 – 2

•High-risk prognostic factors 17p del and/or 11q del

•Active disease meeting ≥ 1 of the IWCLL criteria for requiring treatment
Phase III
NCT02477696
Cancer, All Other
Hematologic
Elie Saikaly, MD
Acerta Pharma BV
Virginia Sanchez
  • Providence Regional Cancer Partnership - Everett